BELL.L

Belluscura Plc
Belluscura PLC - Directorate Change
11th July 2024, 10:30
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 0625W
Belluscura PLC
11 July 2024
 

11 July 2024

 

BELLUSCURA PLC

("Belluscura" or the "Company")

 

Directorate Change

Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that Jonathan Satchell, Non-executive Director, has informed the Board that he intends to step down from his role as a Non-executive Director with effect from 11 July 2024.

Jonathan was appointed to the Board in February 2024 following the acquisition of TMT Acquisition plc by the Company.

Adam Reynolds, Chairman of Belluscura, commented:

"On behalf of the Board, I would like to thank Jonathan for his valued contribution during his time on the Board of Belluscura. His insights and advice have been greatly appreciated since he joined the Board following the Company's acquisition of TMT Acquisition plc and we wish him well with his other roles."

-Ends-

 

For further information please contact:

 

Belluscura plc

Tel: +44 (0)20 3128 8100

Adam Reynolds, Chairman




SPARK Advisory Partners Limited

Nominated Adviser

Tel: +44 (0)20 3368 3550

Neil Baldwin / Jade Bayat




Dowgate Capital Limited

Broker

Tel: +44 (0)20 3903 7715

Russell Cook / Nicholas Chambers




MHP

Financial PR & Investor Relations

Tel: +44 (0)20 3128 8100

email: Belluscura@mhpgroup.com

Katie Hunt/Matthew Taylor


 

About Belluscura plc (https://belluscura.com/)

Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAQKDBDKBKDBOD]]>
TwitterFacebookLinkedIn